Alpine Immune Sciences Deferred Revenue 2011-2026 | ALPN

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Alpine Immune Sciences

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
35.6 M	51.8 M	31.6 M	1.44 M	-	277 K	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
51.8 M	277 K	24.1 M

Quarterly Deferred Revenue Alpine Immune Sciences

2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
10.2 M	16.3 M	30.1 M	37.3 M	40.4 M	35.6 M	46.2 M	42.9 M	51.8 M	51.8 M	48.1 M	49 M	34.5 M	31.6 M	31.6 M	31.6 M	31.6 M	1.44 M	1.44 M	1.44 M	1.44 M	-	-	-	240 K	277 K	405 K	277 K	-	2.01 M	2.01 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
51.8 M	240 K	23.4 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	86.5 M	-	2.43 %	$ 254 M	Germany
Xeris Pharmaceuticals XERS	232 K	$ 6.03	-1.55 %	$ 885 M	USA
I-Mab IMAB	563 K	-	-	$ 866 M	China
UroGen Pharma Ltd. URGN	650 K	$ 19.2	-11.52 %	$ 554 M	Israel
uniQure N.V. QURE	7.63 M	$ 10.89	-30.36 %	$ 530 M	Niderland
Alexion Pharmaceuticals, Inc. ALXN	15.9 M	-	-	$ 40.3 B	USA
AbCellera Biologics ABCL	13.5 M	$ 3.74	3.6 %	$ 1.12 B	Canada
EyeGate Pharmaceuticals, Inc. EYEG	2.69 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	1.3 M	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	1.85 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	2.91 M	-	2.71 %	$ 14 M	USA
Acorda Therapeutics ACOR	227 K	-	-24.86 %	$ 820 K	USA
CureVac N.V. CVAC	158 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	2.19 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	283 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	517 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	6.3 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	240 K	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	18 K	$ 3.36	0.86 %	$ 1.2 M	USA
Agios Pharmaceuticals AGIO	10.9 M	$ 29.16	-3.54 %	$ 1.69 B	USA
Advaxis ADXS	165 K	-	-9.65 %	$ 45.9 M	USA
Alector ALEC	6.68 M	$ 2.19	-9.77 %	$ 226 M	USA
Entera Bio Ltd. ENTX	158 K	$ 1.38	-0.72 %	$ 63.3 M	Israel
Altimmune ALT	19.8 K	$ 4.21	-2.32 %	$ 299 M	USA
Teligent, Inc. TLGT	2.43 M	-	-13.85 %	$ 16.1 M	USA
AlloVir ALVR	2.66 M	-	4.14 %	$ 49.1 M	USA
Evogene Ltd. EVGN	119 K	$ 0.84	-4.24 %	$ 27.9 M	Israel
Ampio Pharmaceuticals AMPE	85.7 K	-	-11.43 %	$ 502 K	USA
Amarin Corporation plc AMRN	2.2 M	$ 13.98	1.27 %	$ 5.7 B	Irlanda
Blueprint Medicines Corporation BPMC	2 M	-	-	$ 8.14 B	USA